Investment professional with over ten years of Wall Street experience. I began my career in investment banking at Merrill Lynch. Following my time at Merrill, I worked for approximately seven years in private equity. Currently, I manage money for both qualified and non-qualified clients. I would classify myself as a long/short investor with a value-based approach.
Michael A. Gayed, CFA, winner of the 2016 Dow Award and 2015 NAAIM Wagner Award, is chief investment strategist and co-portfolio manager at Pension Partners, LLC., an investment advisor which manages mutual funds and separate accounts according to its ATAC strategies. Prior to this role, Gayed served as a portfolio manager for a large international investment group, trading long/short investment ideas in an effort to capture excess returns. From 2004 to 2008, Gayed was a strategist at AmeriCap Advisers LLC, a registered investment advisory firm that managed equity portfolios for large institutional clients. In 2007, he launched his own long/short hedge fund, using various trading strategies focused on taking advantage of stock market anomalies. Follow him on Twitter @pensionpartners and YouTube youtube.com/pensionpartners. He has re-released his father's 1990 book Intermarket Analysis and Investing, now available on Amazon.com.
I hold BS degrees in Biology and Environmental Policy in addition to an M.Ed in Science Education. I have experience as a researcher in the biotech sector. Currently, I teach Biology courses as well as publish articles and research in the fields of science, education and public policy.
The enormous advancement in the biological sciences that is taking place has begun to change the traditional way of practicing medicine. Far-reaching biological products are being approved and news about breakthroughs are occupying the media headlines. However, selecting the biotechnology firms for investment requires not only an understanding of the company's finances, but also deep knowledge of the company's potential and the potential and scientific validity of it's products and technologies.
Our Mission is evaluating biotechnology companies, their products, their technologies, scientists, managements, as well as their finances. Our goal is to impart our readers with the knowledge and insight so that they may have a heightened understanding and appreciation for the biotechnology industry.
The Prohost Letter has been in circulation since 1992. Our readers are comprised of venture capital, fund managers, investors, medical professionals and individuals with one common interest, biotechnology.
Prohost Letter is posted in the members areas on the www.prohostbiotech.com. around 40 times a year. Articles are posted several times a week for subscribers in TODAY'S HIGHLIGHTS section and in News & Comments sector for all website visitors
Please note that the article that you are reading here was originally written on my blog and is republished in Seeking Alpha and other forums. Consequently, I neither track nor respond to comments here. I am sorry! ================ Editors' Note: Seeking Alpha monitors Dr. Damodaran blog and posts relevant articles on his behalf.
Caiman Valores is a Colombian investment consultancy operated by Matt Smith who has over a decade of experience in investment management. He speaks Spanish, has travelled extensively through South America and now lives in Medellin Colombia. His approach to investment analysis relies on gaining a fundamental understanding of the company and then applying a macro-economic overlay. Matt has over two decades of experience in investing and working within investment management and high net worth banking.
He earned a Master of Business Law from the University of Sydney, a Master of Arts in International Relations and a Bachelor Degree in Political Science and Economics from the University of New South Wales.
Please feel free to contact him if you have questions regarding investments, writing, or speaking opportunities via email at firstname.lastname@example.org.
Dr Pirrong is Professor of Finance, and Energy Markets Director for the Global Energy Management Institute at the Bauer College of Business of the University of Houston. He was previously Watson Family Professor of Commodity and Financial Risk Management at Oklahoma State University, and a faculty member at the University of Michigan, the University of Chicago, and Washington University. Professor Pirrong's research focuses on the organization of financial exchanges, derivatives clearing, competition between exchanges, commodity markets, derivatives market manipulation, the relation between market fundamentals and commodity price dynamics, and the implications of this relation for the pricing of commodity derivatives. He has published 30 articles in professional publications, is the author of three books, and has consulted widely, primarily on commodity and market manipulation-related issues. He holds a Ph.D. in business economics from the University of Chicago.
Larry MacDonald worked as an economist for many years and now manages his investment portfolio while writing about business and investing topics for leading Canadian publications. He also is the author of several business books.
“Sold At TheTop” is the snarky pseudonym for the organic blogger that maintains the reasonably popular and, dare I say, possibly even slightly influential web log PaperEconomy (www.papereconomy.com).
“Sold”, as he prefers to be called (especially by his wife under certain saucy circumstances… mmmm…) is not a professional economist, analyst or stock trader and has neither been trained in finance nor statistics.
What Sold offers is a dedicated and serious passion for macroeconomic analysis and further, for the creation of striking, some say even artistic, visualizations of macroeconomic data. Though not a “perma-bear” Sold is very bearish about the current state and future of the American economy subscribing whole heartedly to notion that the recent financial crisis is but the second act of an immense systemic unwind that commenced, more or less, in the year 2000.
Sold is NOT A PESSIMIST by nature but a true skeptic and a realist that prefers solid and sustained evidence of fundamental economic recovery to “Goldilocks”, “Green Shoots”, “Mustard Seeds” and wholesale speculation. Further, Sold believes that the evidence for rational and efficient markets as well as collective wisdom is scant.
In his spare time Sold works as an independent software consultant spewing out cutting edge code like he’s spraying silly string.
Edward Harrison is the founder of the blog Credit Writedowns (www.creditwritedowns.com) and is a finance specialist at Global Macro Advisors. Previously, Edward was a strategy and finance executive at Deutsche Bank, Bain, and Yahoo. He started his career as a diplomat and speaks German, Dutch, Swedish, Spanish and French. Edward holds an MBA from Columbia University and a BA in Economics from Dartmouth College. Follow him on Twitter at twitter.com/edwardnh. Contact him at edh at creditwritedowns dot com as that's the only mailbox he reads regularly.
Kenneth S. Hackel C.F.A., Biography
Kenneth S. Hackel is founder and President of CT Capital LLC, an institutional investment advisory firm specializing in the analysis of corporate cash flow and cost of capital in investment decision making. Until 1996, he was President of Systematic Financial Management Inc., (SFM) a multi-billion dollar institutional investment firm he conceived and founded in 1982. At SFM, Kenneth successfully implemented his free cash flow-based investment philosophy in managing funds for institutional investors across multiple US equity investment disciplines.
Kenneth's upcoming book, "Security Valuation and Risk Analysis: Assessing Value in Investment Decision-Making", to be published by McGraw Hill later this November, significantly extends the theories and analysis presented in his earlier book, "Cash Flow and Security Analysis," 2nd edition (McGraw Hill, 1995). His new book provides extensive analysis and discussion of innovative methods for cost of capital and return on invested capital that are not dependent upon generally accepted accounting principles or market-derived measures of stock volatility. Instead, the models are based on cash flows and extensive credit analysis. To this end, half the book is devoted to the understanding of cash flow; half to cost of capital, as risk to cash flows are meticulously expounded upon. The analysis of risk represents, according to Mr. Hackel, the single most important under-explored factor in security analysis and the primary reason for investor disappointment of their investment returns.
He posits that using fundamental factors to calculate cost of equity capital (reflecting a company's operating and financial risk, capital structure, and miscellaneous intrinsic items) and return on invested capital based upon free cash flow generation (in lieu of traditional earnings or EBITDA-based measures) more accurately reflect the underlying financial profitability and stability of a firm, its growth potential and value enhancement level. Kenneth believes that while beta measures stock volatility, it is, at best, a very loose surrogate for financial health. Consequently, using a more robust discount rate (to model and discount free cash flows) to arrive at 'fair value' will provide a more accurate comparison to current valuation levels, thus leading to more accurate trading signals. He illustrates the use of a comprehensive cost of capital credit worksheet utilizing 50+ credit variables in place of the popular Capital Asset Pricing Model in divining an entity's true cost of equity, which results in superior investment performance with considerably lower risk.
Ken is the author of many articles on security valuation and analysis, and pioneered the use of adding a percentage of excess corporate expenditures to free cash flow. He is internationally recognized as a leading expert in valuation analysis, having also created the use of free cash flow in lieu of EBITDA in ROIC analysis. EBITDA, he explains, is a deficient metric, in many respects.
Ken is accepted to be the sole investment advisor in US equity mutual fund history to take over management of the worst performing mutual fund, and in a single year turn it into the best performing fund.
With over 35 years of investment experience, he has consulted on mergers and acquisitions, including fairness opinions. His work has been published in leading academic journals as well as leading financial news media, and is quoted worldwide. He is a graduate of City College of New York and earned his MBA (Finance) from Baruch College.
His blog may be read at www.credittrends.com and his twitter @credittrends.
Mike Havrilla is a former pharmacist (retail and home infusion settings), biotech stock trader, and writer with experience that includes full-time online trading since 2009, working as a full-time pharmacist from 2004-2009, and writing for investors since 2007. Mike holds Doctor of Pharmacy (PharmD) and Bachelor of Science (Biology) degrees from the University of Pittsburgh and worked in the pharmaceutical industry for Wyeth prior to pharmacy school. He is also an avid runner and has completed over 20 marathons with a personal best time under three hours for the 26.2 mile race and under 80 minutes for the half marathon. Mike merged his former publishing business with BioRunUp.com / Mark Messier in October 2010, creating a new online biotech stock research and trading subscription service.
China has become the #2 pharmaceutical market years ahead of projections and continues to be the fastest growing market in the world. China is $50 billion dollars a year into life science and healthcare development through over 160 government funding programs. VC investment, M&A transactions and cross-border partnering deals in China were all up significantly in 2012.
ChinaBio® Today focuses exclusively on the rapidly evolving life science industry in China, including biotech, pharma, medical device, diagnostics, services and tools. From our offices in Shanghai and San Diego, our industry analysts provide daily news, commentary and analysis on public and private China life science companies, as well as events and global issues affecting the China market.
Visit: ChinaBio Today (http://www.chinabiotoday.com)
ChinaBio LLC (http://www.chinabiollc.com)
I'm a well-informed retail investor and post on SA in order to expose my thought process to critical examination and comment from readers. It makes me a better investor.
I'm particularly proud of bullish macro articles posted in 2009 and later, in which I presented ideas that encouraged me to invest very profitably in a rising market. I also did articles on individual stocks, many of which contained insights not available elsewhere. Finally, I wrote a number of thoughtful articles critical of financialism and the lack of ethics on Wall Street.
I do not post for compensation, as I am concerned that editorial policy encourages and pays a premium for articles that invite the reader to speculate on the short term movements of microcaps, penny stocks, and controversial issues. The best way for me to monetize my insights is to invest accordingly.
As a retail investor, I don't give investment advice. I write about what I'm investing in, and the thought process involved in decision making and stock selection. Hopefully some of what I write is of benefit to others, by sharing my experience as I interpret it and helping them improve their investment thinking and process.
Greentech Media (GTM) produces industry-leading news, research, and conferences in the business-to-business greentech market. Our coverage areas include solar, smart grid, energy efficiency, wind, and other non-incumbent energy markets. GTM Research, the research arm of the company, produces competitive intelligence reports and data subscriptions.
Read additional coverage on the renewable energy market on our website: www.greentechmedia.com, and gain additional insight by signing up for our research services at www.gtmresearch.com.
You can also follow us on twitter: @greentechmedia, or like us on Facebook: facebook.com/greentechmedia.